Candel Therapeutics (NASDAQ:CADL – Get Free Report) posted its earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.17), Zacks reports.
Candel Therapeutics Stock Performance
Candel Therapeutics stock opened at $8.75 on Friday. Candel Therapeutics has a 1 year low of $1.34 and a 1 year high of $14.60. The firm has a 50 day moving average price of $8.21 and a 200 day moving average price of $6.94. The company has a market cap of $284.17 million, a price-to-earnings ratio of -5.06 and a beta of -1.29.
Insider Activity at Candel Therapeutics
In other Candel Therapeutics news, insider Francesca Barone sold 13,534 shares of Candel Therapeutics stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total transaction of $97,715.48. Following the transaction, the insider now directly owns 110,673 shares of the company’s stock, valued at $799,059.06. The trade was a 10.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CTO Seshu Tyagarajan sold 14,322 shares of Candel Therapeutics stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total transaction of $103,404.84. Following the transaction, the chief technology officer now directly owns 96,790 shares in the company, valued at approximately $698,823.80. This trade represents a 12.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 41,529 shares of company stock worth $313,512. 41.60% of the stock is owned by company insiders.
Analyst Ratings Changes
View Our Latest Stock Report on Candel Therapeutics
Candel Therapeutics Company Profile
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
See Also
- Five stocks we like better than Candel Therapeutics
- What is Insider Trading? What You Can Learn from Insider Trading
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- 3 Monster Growth Stocks to Buy Now
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
- What Do S&P 500 Stocks Tell Investors About the Market?
- Why Costco Stock Is Poised to Hit $1,000 Again Soon
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.